Compare McKesson Corporation (MCK) vs T-Rex 2X Inverse MSTR Daily Target ETF (MSTZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs T-Rex 2X Inverse MSTR Daily Target ETF — how do they compare? McKesson Corporation trades at $824 (market cap $97.35B), while T-Rex 2X Inverse MSTR Daily Target ETF trades at $10.86. The key difference: McKesson Corporation pays a 0.39% dividend while T-Rex 2X Inverse MSTR Daily Target ETF pays none, and McKesson Corporation is trading nearer its 52-week high, T-Rex 2X Inverse MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals.
| MCK | MSTZ | |
|---|---|---|
Market Cap | $97.35B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $995.69 | $27.92 |
52-Week Low | $659.01 | $3.50 |
Enterprise Value | $101.98B | — |
Dividend Yield | 0.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
MSTZ stock trades at $11.49, down 6.2% over the past day, amid a mixed technical backdrop with a bullish moving average signal but neutral oscillators. Key support sits at $11, with resistance at $13. Financial ratios including P/E, P/S, and ROE are unavailable, limiting fundamental clarity. Recent news highlights ETF performance trends but lacks direct company updates.
The outlook remains uncertain due to incomplete financial data; upside potential hinges on positive earnings surprises or guidance, while risks include weak fundamentals and market volatility. Investors require verified financials to assess valuation and growth prospects accurately.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About T-Rex 2X Inverse MSTR Daily Target ETF
MSTZ is a leveraged ETF that seeks daily investment results corresponding to 200% of the inverse (opposite) of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bearish position on MSTR, a company known for its large Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from its stated daily objective.
Read more on MSTZ →
